It is very uncertain whether summary of findings table ‐ High sodium dialysate changes adverse events compared with standard sodium dialysate (very low certainty).
Prednisone showed no clear difference in persistent kidney disease at any time after treatment compared with placebo or supportive treatment (moderate certainty).
Prednisone showed no clear difference in children with any continuing kidney disease at 3 months compared with placebo or supportive treatment (moderate certainty).
Prednisone showed no clear difference in children with any continuing kidney disease at 6 months compared with placebo or supportive treatment (moderate certainty).
Prednisone showed no clear difference in children with any continuing kidney disease at 12 months compared with placebo or supportive treatment (low certainty).
Prednisone showed no clear difference in number developing severe kidney disease compared with placebo or supportive treatment (low certainty).
Standard interferon showed no clear difference in death compared with placebo or control (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in sustained virological response 6 months after stopping treatment compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in treatment discontinuation compared with standard interferon (low certainty).
Pegylated interferon alpha‐2a showed no clear difference in adverse events compared with standard interferon (low certainty).
The review found no eligible studies for this question.
High showed no clear difference in PEG interferon alpha‐2a compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).
High showed no clear difference in PEG interferon alpha‐2b compared with low dose pegylated interferon alpha‐2a or alpha‐2b (low certainty).
High showed no clear difference in PEG interferon (combined) compared with low dose pegylated interferon alpha‐2a or alpha‐2b (moderate certainty).
The review found no eligible studies for this question.
Standard interferon showed no clear difference in relapse(recurrence after stopping intervention) compared with placebo or control (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.